Clinical trials: Withdrawal
Opioid-Related Disorders
Phase IIa Study of AV411, a Glial Activation Inhibitor, for Opioid Withdrawal
Repeated use and/or abuse of opioid medications is generally associated with a characteristic withdrawal syndrome that develops after cessation of drug administration.
- Trial name
- AV411 (NCT00723177)
- Testing
- AV411
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- New York State Psychiatric Institute
Nicotine Dependence, Nicotine Withdrawal
Progesterone and Brain Imaging Study
Male and female smokers were recruited to undergo 2 phases of smoking cessation. Each phase was 4 days long and involved 3 brain-imaging scans, blood draws and an intervention involving progesterone or a matched placebo.
- Trial name
- NCT01954966
- Testing
- Progesterone
- Where
- United States
- Volunteers
- 81 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Opioid-use Disorder
Surmounting Withdrawal to Initiate Fast Treatment With Naltrexone
This study compares two methods of initiating treatment with extended-release naltrexone (XR-NTX) when implemented at community-based inpatient or residential programs.
- Trial name
- SWIFT (NCT04762537)
- Testing
- Standard Induction Procedure (SP), Rapid Induction Procedure (RP)
- Where
- 6 sites in United States
- Volunteers
- 415 people
- Sponsor
- New York State Psychiatric Institute
Smoking
Long-term Varenicline Treatment for Smoking Cessation
This is a clinical study of the efficacy and safety of up to 52 weeks of varenicline therapy in conjunction with individual counseling for smoking cessation.
- Trial name
- NCT00828113
- Testing
- varenicline, Individual smoking cessation counseling
- Where
- 2 sites in United States
- Volunteers
- 101 people, healthy volunteers welcome
- Sponsor
- University of Wisconsin, Madison
Type 2 Diabetes Mellitus
Randomized Sitagliptin Withdrawal Study (MK-0431-845)
This is a trial of continuing sitagliptin versus withdrawing sitagliptin in participants with Type 2 diabetes mellitus (T2DM) and inadequate glycemic control who initiate and titrate insulin glargine (LANTUS®) based on a…
- Trial name
- NCT02738879
- Testing
- Sitagliptin, Metformin, Metformin XR
- Volunteers
- 746 people
- Sponsor
- Merck Sharp & Dohme LLC
Cocaine Dependence, Opiate Dependence
Cocaine Withdrawal and Pharmacotherapy Response
A total of 120 male and female opioid dependent cocaine users will participate in this study. This study will be a 8-week double-blind, placebo controlled study examining the dose-dependent effects of carvedilol (up to 50 mg/day)…
- Trial name
- Carvedilol (NCT00566969)
- Testing
- sugar pill, Carvedilol 25 mg, Carvedilol 50 mg
- Where
- United States
- Volunteers
- 106 people
- Sponsor
- Yale University
Chronic Kidney Disease, Dialysis
A Phase 3, Randomized, Double Blind, Placebo-Controlled, Multi-Center, Withdrawal Study of MCI-196 in CKD on Dialysis With Hyperphosphatemia
This is a phase III multi-centre study in three periods: the first period is a phosphate binder washout for 4 weeks, the second period is an open-label, flexible dose titration, the third period is a placebo-controlled withdrawal…
- Conditions
- Chronic Kidney Disease, Dialysis, Hyperphosphatemia
- Trial name
- NCT00506441
- Testing
- MCI-196
- Where
- 39 sites in United States, Puerto Rico
- Volunteers
- 245 people
- Sponsor
- Tanabe Pharma Corporation
Chronic Lower Back Pain, Chronic Pain
Buprenorphine (CAM2038) in Subjects With a Recent History of Moderate to Severe Chronic Low Back Pain
This is a Phase III, placebo-controlled, multicenter study with an enriched-enrollment withdrawal (EEW) design to evaluate the efficacy and safety of CAM2038 in opioid-experienced subjects with moderate to severe CLBP that…
- Trial name
- CAM2038 (NCT02946073)
- Testing
- buprenorphine
- Where
- 69 sites in United States
- Volunteers
- 1,053 people
- Sponsor
- Braeburn Pharmaceuticals
Alcohol-Related Disorders, Alcohol Dependence
Acamprosate to Reduce Symptoms of Alcohol Withdrawal
This study will examine whether a new drug called acamprosate can be helpful for alcohol withdrawal, a result of drinking high amounts of alcohol for long periods of time.
- Conditions
- Alcohol-Related Disorders, Alcohol Dependence, Alcoholism, Healthy Volunteer
- Trial name
- NCT00106106
- Testing
- NMR-spectroscopy, Oral acamprosate
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- National Institutes of Health Clinical Center (CC)
Alcohol Dependence
Gabapentin for Abstinence Initiation in Alcohol Dependence
Primary Hypotheses: 1. Gabapentin will significantly reduce alcohol consumption and promote abstinence as compared to placebo. The primary outcome measure will be the number of the heavy drinking days (defined as any day where…
- Trial name
- GAINS (NCT01141049)
- Testing
- Gabapentin
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- New York State Psychiatric Institute
Smoking, HIV-1-infection
Effects of Metformin During Nicotine Withdrawal
The purpose of this study is to test the effects of a medication called metformin (Glucophage®) on smoking behavior. This medication is FDA-approved for treatment of type-2 diabetes.
- Trial name
- MEP (NCT03593538)
- Testing
- Metformin
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Opioid Use, Unspecified With Withdrawal, Opioid-Induced Disorders
Adjunct Methadone to Decrease the Duration of Mechanical Ventilation in the Medical Intensive Care Unit
The purpose of this study is to determine if administering methadone to mechanically ventilated patients in the medical intensive care unit (ICU) requiring continuous infusions of sedatives and analgesics will decrease the time…
- Conditions
- Opioid Use, Unspecified With Withdrawal, Opioid-Induced Disorders, Delirium
- Trial name
- NCT02025855
- Testing
- Methadone
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Henry Ford Health System
Alcohol Dependence, Bipolar Disorder
Acamprosate vs. Placebo in Bipolar Alcoholics
To conduct a double-blind, randomized, placebo-controlled outpatient clinical trial of acamprosate in individuals with alcohol dependence and bipolar disorder who are also receiving mood stabilizing medication.
- Trial name
- NCT00466661
- Testing
- Acamprosate
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Medical University of South Carolina
Kidney Transplantation
Pharmacokinetic Profile of Myfortic in Combination With Tacrolimus in Fed Versus Fasting State
Literature regarding the effect of food on the pharmacokinetic (PK) profile of enteric-coated mycophenolate sodium combined with tacrolimus and corticosteroid withdrawal is lacking.
- Trial name
- NCT00585468
- Testing
- Myfortic
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- University of Utah
Substance-Related Disorders
Palonosetron and Hydroxyzine to Reduce Opioid Withdrawal
Opioid medications are commonly used for pain relief. When given over time, physical dependence can occur. This results in unpleasant side effects--such as agitation and nausea--if opioid medications are suddenly stopped.
- Trial name
- NCT00661674
- Testing
- Palonosetron, Hydroxyzine
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Stanford University
Substance-Related Disorders
Functional Magnetic Resonance Imaging of Opioid Withdrawal in Healthy Human Volunteers
Opioid medications are commonly used for pain relief. When given over time, physical dependence can occur. This results in unpleasant side effects--such as agitation and nausea--if opioid medications are suddenly stopped.
- Trial name
- NCT01006707
- Testing
- Ondansetron
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Stanford University
Hyperphosphatemia
An 8-Week Study to Evaluate Tenapanor in the Treatment of Hyperphosphatemia in End-Stage Renal Disease Patients on Hemodialysis (ESRD-HD)
This phase 3, 8-week, randomized, double-blind, parallel group, multi-center study with a 4-week, placebo-controlled, randomized withdrawal period will evaluate the efficacy, safety and tolerability of Tenapanor to treat…
- Trial name
- NCT02675998
- Testing
- Tenapanor
- Where
- 32 sites in United States
- Volunteers
- 219 people
- Sponsor
- Ardelyx
Diabetic Peripheral Neuropathy
A Study to Evaluate the Efficacy, Safety, and Tolerability of Tapentadol ER Compared With Placebo in Patients With Chronic, Painful Diabetic Peripheral Neuropathy
The purpose of this study is to evaluate the efficacy, safety, and tolerability of orally administered tapentadol extended release (ER) at dosages of 100 to 250 mg twice daily compared with placebo in patients with moderate to…
- Trial name
- NCT01041859
- Testing
- Tapentadol extended release (ER)
- Where
- 72 sites in United States, Canada and 1 more
- Volunteers
- 460 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Cannabis Dependence, Alcohol Dependence
Pharmacological Treatment of Comorbid Alcohol and Marijuana Withdrawal and Dependence
The primary aim of the supplemental study is to provide POC testing of aprepitant as a treatment for comorbid alcohol and cannabis dependence.
- Conditions
- Cannabis Dependence, Alcohol Dependence, Cannabis Use Disorder, Alcohol Use Disorder
- Trial name
- NCT02210195
- Testing
- aprepitant, Manual-guided behavioral counseling
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- The Scripps Research Institute
Psoriasis
A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis With Randomized Withdrawal and Retreatment
The purpose of this study is to evaluate the efficacy, safety, and tolerability of guselkumab (CNTO 1959) in the treatment of participants with moderate to severe plaque-type psoriasis (scaly skin rash).
- Trial name
- VOYAGE 2 (NCT02207244)
- Testing
- Guselkumab 100 mg, Adalimumab
- Where
- 93 sites in United States, Australia and 7 more
- Volunteers
- 992 people
- Sponsor
- Janssen Research & Development, LLC